Moreover, caspase-1 has been reported to be associated with HCC inflammatory microenvironment, epithelial–mesenchymal transition (EMT) phenotype, and sorafenib treatment, which reduces caspase-1/IL1B expression by suppressing TLR4/stat3/SUMO1 signaling pathway7. The gene discussed is CASP1; the disease is hepatocellular carcinoma.